AAP
ZYNE

Arax Advisory Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Arax Advisory Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,648
Closed -$5K – 1362
2022
Q3 		$5K Hold
6,648
– – ﹤0.01% 832
2022
Q2 		$8K Buy
6,648
+1,648
+33% +$2.1K ﹤0.01% 694
2022
Q1 		$10K Buy
5,000
+2,500
+100% +$5.94K ﹤0.01% 663
2021
Q4 		$7K Hold
2,500
– – ﹤0.01% 724
2021
Q3 		$11K Buy
+2,500
New +$11.2K ﹤0.01% 636

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Arax Advisory Partners's ZYNE Position: Q4 2022 in Review

Arax Advisory Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 6,648 shares — an estimated $5K sold.

Arax Advisory Partners first reported a position in ZYNE in Q3 2021 and held it in 5 quarters. The position peaked at $11K in Q3 2021. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • Arax Advisory Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Arax Advisory Partners sold 6,648 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $5K.
  • Arax Advisory Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2021 and held it in 5 quarters.
  • Arax Advisory Partners's Zynerba Pharmaceuticals, Inc position peaked at $11K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Arax Advisory Partners's 13F filing for Q4 2022, filed 24 Feb 2023.